Taiwan · Delayed Price · Currency is TWD BioLASCO Taiwan Statistics
Total Valuation
BioLASCO Taiwan has a market cap or net worth of TWD 754.27 million. The enterprise value is 700.02 million.
| Market Cap | 754.27M |
| Enterprise Value | 700.02M |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Aug 7, 2026 |
Share Statistics
BioLASCO Taiwan has 25.61 million shares outstanding. The number of shares has decreased by -0.07% in one year.
| Current Share Class | 25.61M |
| Shares Outstanding | 25.61M |
| Shares Change (YoY) | -0.07% |
| Shares Change (QoQ) | -1.24% |
| Owned by Insiders (%) | 29.95% |
| Owned by Institutions (%) | n/a |
| Float | 15.87M |
Valuation Ratios
The trailing PE ratio is 18.53.
| PE Ratio | 18.53 |
| Forward PE | n/a |
| PS Ratio | 2.92 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 1.77 |
| P/FCF Ratio | 22.36 |
| P/OCF Ratio | 17.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.67, with an EV/FCF ratio of 20.75.
| EV / Earnings | 17.12 |
| EV / Sales | 2.71 |
| EV / EBITDA | 11.67 |
| EV / EBIT | 14.86 |
| EV / FCF | 20.75 |
Financial Position
The company has a current ratio of 2.32, with a Debt / Equity ratio of 0.20.
| Current Ratio | 2.32 |
| Quick Ratio | 1.91 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 1.48 |
| Debt / FCF | 2.58 |
| Interest Coverage | 21.67 |
Financial Efficiency
Return on equity (ROE) is 9.56% and return on invested capital (ROIC) is 10.40%.
| Return on Equity (ROE) | 9.56% |
| Return on Assets (ROA) | 4.74% |
| Return on Invested Capital (ROIC) | 10.40% |
| Return on Capital Employed (ROCE) | 9.13% |
| Weighted Average Cost of Capital (WACC) | 4.88% |
| Revenue Per Employee | 2.84M |
| Profits Per Employee | 449,341 |
| Employee Count | 91 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 5.26 |
Taxes
In the past 12 months, BioLASCO Taiwan has paid 6.92 million in taxes.
| Income Tax | 6.92M |
| Effective Tax Rate | 14.47% |
Stock Price Statistics
The stock price has decreased by -9.38% in the last 52 weeks. The beta is 0.17, so BioLASCO Taiwan's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -9.38% |
| 50-Day Moving Average | 29.72 |
| 200-Day Moving Average | 30.19 |
| Relative Strength Index (RSI) | 49.71 |
| Average Volume (20 Days) | 10,798 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioLASCO Taiwan had revenue of TWD 258.04 million and earned 40.89 million in profits. Earnings per share was 1.59.
| Revenue | 258.04M |
| Gross Profit | 101.69M |
| Operating Income | 45.88M |
| Pretax Income | 47.81M |
| Net Income | 40.89M |
| EBITDA | 58.75M |
| EBIT | 45.88M |
| Earnings Per Share (EPS) | 1.59 |
Balance Sheet
The company has 141.27 million in cash and 87.01 million in debt, with a net cash position of 54.26 million or 2.12 per share.
| Cash & Cash Equivalents | 141.27M |
| Total Debt | 87.01M |
| Net Cash | 54.26M |
| Net Cash Per Share | 2.12 |
| Equity (Book Value) | 427.45M |
| Book Value Per Share | 16.88 |
| Working Capital | 125.73M |
Cash Flow
In the last 12 months, operating cash flow was 43.89 million and capital expenditures -10.15 million, giving a free cash flow of 33.73 million.
| Operating Cash Flow | 43.89M |
| Capital Expenditures | -10.15M |
| Depreciation & Amortization | 12.87M |
| Net Borrowing | -17.38M |
| Free Cash Flow | 33.73M |
| FCF Per Share | 1.32 |
Margins
Gross margin is 39.41%, with operating and profit margins of 17.78% and 15.85%.
| Gross Margin | 39.41% |
| Operating Margin | 17.78% |
| Pretax Margin | 18.53% |
| Profit Margin | 15.85% |
| EBITDA Margin | 22.77% |
| EBIT Margin | 17.78% |
| FCF Margin | 13.07% |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 5.09%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 5.09% |
| Dividend Growth (YoY) | 3.33% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 93.96% |
| Buyback Yield | 0.07% |
| Shareholder Yield | 5.16% |
| Earnings Yield | 5.42% |
| FCF Yield | 4.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 30, 2018. It was a forward split with a ratio of 1.055.
| Last Split Date | Jul 30, 2018 |
| Split Type | Forward |
| Split Ratio | 1.055 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |